Drugs Made In America Acquisition Corp. functions as a special purpose acquisition company, or SPAC, established to pursue a business combination. The company aims to identify and merge with, exchange capital stock, acquire assets from, or reorganize with one or more businesses, specifically targeting the U.S. pharmaceutical industry. Its core strategy is to invest in entities focused on the domestic manufacturing of approved pharmaceuticals, active pharmaceutical ingredients, and related contract development and manufacturing services. The ultimate objective is to bolster American pharmaceutical independence and enhance the resilience of the U.S. medical supply chain by onshoring critical drug production. Incorporated in 2024, the company successfully completed its initial public offering in January 2025, raising $200 million, with its funds held in a trust account while it actively seeks a suitable acquisition target.